BEST STARTUP CATEGORY
PRIX GALIEN USA
NOMINEE 2024

Ymmunobio
3rd Place

Grant recipient of
Innosuisse
Swiss Innovation Agency

Ymmunobio

A Paradigm Change in Oncology: Precision Targeting with First-in-Class NPTXR ADCs

- ✓ Highly selective target in 17+ solid tumors, zero expression in normal tissue
- ✓ Lead asset YB-811 addresses blockbuster indications with >$100B market potential
- ✓ Clear exit strategy: via IPO, licensing ($800M–$1.2B), or spinouts
- ✓ Projected ROI: 20–40x with long-term upside from multiple follow-on indications

Ymmunobio: Precision Oncology via NPTXR-Targeted Conjugates

Transforming solid tumor treatment with novel, highly selective compounds

The Problem

- Existing target antigens also found in healthy tissues → off-tumor toxicity
- Crowded space → few tumor-specific, druggable targets remaining

Our Solution

- First-in-class program targeting NPTXR, a tumor-selective antigen
- Expressed in 17+ solid tumors
- Undetectable in healthy tissues
- Preclinical data show potent efficacy and clean safety profile

Market Opportunity

- Estimated share in Total Addressable Market (TAM) > $100B
- Addresses unmet needs in GI, GU, Breast and Lung cancers
- IP-protected; first mover in NPTXR targeting

Why Now

- Growing demand for safer, tumor-specific compounds
- IND-enabling studies in progress; data-readiness in 2026
- Targeted therapy M&A activities surging

2026 Funding Goal

CHF 15M (US$ 18.5M)

- IND-enabling & Phase I readiness
- Toxicology studies
- Regulatory preparation

2027/28 Funding Goal

CHF 70M (US$ 86M)

- PoC in Humans: Phase I Dose Escalation & Expansion Cohort

Exit Path

- Licensing Post-PoC
- IPO & Spinouts

Strategic Opportunity Across High-Value Oncology Markets



- Many different cancers as top opportunities (high prevalence, strong NPTXR expression, and large TAM);
- Broad tumor-selective potential of our program with minimal off-target risk.

The strategic potential of NPTXR-targeted therapies: **TAM (X-axis)**, **NPTXR prevalence (Y-axis)**, and **global incidence (bubble size)** for 13 solid tumor indications.

Exit Scenarios & Investor ROI

Scenario 1
Licensing Post – PoC

- **Upfront**: US$ 80 – 120M,
- **Milestones**: US$ 500 – 700M,
- **Royalty**: 10-12% on all solid tumors;
- Increasing royalties as additional indications are launched

Scenario 2
IPO & Spinouts

- IPO value US$ 800M – 1.2B with YB-811 first-in-class ADC.
- Future subsidiaries:
  - Ymmuno-BT (BiTCE/TriTCE),
  - Ymmuno-R (Radiopharmaceuticals)
- Each unit to be independently financed or partnered post-IPO



Investor ROI

- Entry valuation: US$ 20 – 25M
- Exit: US$ 800 – 1.2B
- **ROI: 20 – 40x**

Ymmunobio Executive Summary

THE COMPANY & TEAM

- Ymmunobio was founded in 2021 by **two experienced drug developers**
- **IP acquisition for antibody & strong IP around new tumor target** from Nagoya University, Japan
- **Experienced team supported by leading scientific advisors** (academic, clinical development, CMC, BD, legal)

SCIENCE

- **First in class Target:** detected in **+17 tumors, not in healthy tissue, prevalence < 98%, 100% tumor cells +!**

THERANOSTICS PLATFORM

- Fully humanized antibody targeting NPTXR as basis for **new treatment options**: YB-800
  - **YB-811:** dual payload; 3rd generation linker ADC; ADR 4+4=8
  - **YB-820/YB-821:** Bi-specific T-Cell engager (aCD3)
  - **YB-830, YB-831 & YB-832:** (^{177}Lu,^{161}Tb), RLT & Scanning in collaboration with PSI* funded by Innosuisse**
  - **YB-880:** Tri-specific T-Cell engager (aCD3 & aCD28)
  - **Liquid biopsy diagnostic test -** development with partner **EVIIVE AG**

IP

- **Ymmunobio owns IP:** MoU US ‘23 & ‘24, JPN ‘24; CoM submitted EP ’24, PCT ’25, US/JPN/CN/SK ‘26

MARKET TARGET

- **Gastro-intestinal, Genitourinary, Lung and Breast cancer**

COMPETITORS

- **No competitor** on NPTXR; **Tumor Target is “locked-in”** by both patents (MoU and CoM)

FUNDRAISING

- Raised **CHF 2.6 M** (founders (CHF 940K), private investors, one institutional investor)
- Innosuisse** **Grant** (non-dilutive) awarded: **CHF 350’000** for developing **RLT** with PSI*
- **Short term IND readiness: CHF 15M (US$ 18.5), Long term PoC in humans: CHF 70M (US$ 86M)**

EXIT SCENARIOS

- **Major: After PoC in Humans; Minor: IND approval**

* PSI = Paul Scherrer Institute, Switzerland; ** Innosuisse = Swiss Government Innovation Agency

Grant recipient of
Innosuisse
Swiss Innovation Agency

Program, Pipeline and Partnerships

- ✓ Our NPTXR-based platform spans ADCs, BiTCEs, TriTCE and Radiopharmaceuticals
- ✓ Built to address diverse tumor types and maximize therapeutic value
- ✓ World-class strategic global collaborations

Therapeutic Modality Pipeline

hmAb - ADC – Radionuclide – BiTCE – TriTCE

Innovation project supported by

Partnerships

YUMAB | TE Meds | YUMAB | YUMAB | PSI











Programs	**hmAb* YB-800**	**ADC** YB-811**	**BiTCE*** YB-820/821**	**TriTCE**** YB-880**	**Radionuclide YB-830/831/(832 - imaging)**
Status	**Research tool** (FACS, ELISA, IHC, WB,…)	**Preclinical PoC IND end 2026**	**Lead Optimization**	**Lead Optimization**	**Lead Candidate Selection Therapeutic & Diagnostic** (Imaging)

*hmAb: humanized monoclonal antibody; **ADC: Antibody Drug Conjugate; ***BiTCE: Bi-specific T-Cell Engager (aCD3); ****TriTCE: Tri-specific T-Cell engager (aCD3 & aCD28)
Yumab: Yumab GmbH, Germany; TE Meds: TE Meds, Taiwan; PSI: Paul-Scherrer-Institute, Switzerland

BEST STARTUP CATEGORY
PRIX GALIEN USA
NOMINEE 2024
Ymmunobio
3rd Place

Grant recipient of
Innosuisse
Swiss Innovation Agency

Development Plan and Clinical Path

- ✓ Rapid path to clinical proof-of-concept with scalable development strategy
- ✓ Clear roadmap to IND and early human data in high-prevalence solid tumors
- ✓ Modular CMC and biomarker-driven approach enable cost-effective, risk-mitigated progression

Development Plan for YB-811 lead ADC until PoC in Humans

Fund Raising: CHF 15M (US$ 18.5M) – CMC, Tox Studies & IND Submission



Grant recipient of
Innosuisse
Swiss Innovation Agency

Ymmunobio

Background

- ✓ Proven presence of NPTXR in 17+ solid tumors
- ✓ Highest prevalence in patients: up to 98%
- ✓ Only expressed in tumor tissue; no presence in healthy tissue
- ✓ When expressed, ALL tumor cells express NPTXR
- ✓ Positive in vitro and in vivo results with experimental ADCs

Expression in Human Cancer & Healthy Tissue

Tumor Tissue (n=26-66)



Healthy Tissue (n=5)



Strong cell membrane expression in solid tumors

- Highest H-score in Bladder, Cervix and Squamous Lung cancer
- Target validation completed*

**Carter et al.: Target identification and validation of cell surface antigens Endocrine-Related Cancer (2004) 11 659–687*

No cell membrane expression in healthy tissue;

Limited unspecific cross reactivity:

- mucosal epithelium possibly due to cross reactivity with sugars in the mucus
- distal tubule in the kidney (intracellular)

NPTXR Expression in Cancer

High Prevalence and H-Scores

Cancer	Prevalence			H-Score			
	#	+ [%]	- [%]	H	M	L	Total = 3H+2M+L
Bladder	51	**98.3**	1.7	89.5	5.3	3.5	**282.6**
Cervix	43	**89.7**	10.3	48.7	33.3	7.7	**220.4**
sq NSCLC	50	**82.0**	3.8	54.0	20.0	8.0	**210.0**
Hepato-cholangio	14	**92.9**	7.1	42.9	28.6	21.4	**207.2**
Pancreas	48	**79.2**	20.8	47.9	27.1	4.2	**202.1**
Breast (excl TNBC)	66	**92.4**	7.6	24.2	51.5	16.7	**192.3**
Gastric	136	**82.5**	17.5	39.4	28.2	14.6	**189.8**
Colon	45	**97.8**	2.2	15.6	48.9	33.3	**177.9**
Endometrium	39	**71.8**	28.2	28.2	33.3	10.3	**161.5**
TN Breast	86	**68.6**	31.4	27.9	27.9	12.8	**152.3**
Cholangio	54	**62.9**	37.1	25.9	25.9	11.1	**140.6**
Ovaries	47	**57.4**	42.6	25.5	19.1	12.8	**127.5**
Esophagus	60	**61.5**	38.5	18.2	25.0	18.3	**122.9**

sq NSCLC cell highly expressing NPTXR on cell membrane



Methodology: Independent validation from two labs (Prof. Wennemuth & Prof. Kanda including review by Pathologist Dr. Lyndin) in several solid tumors. Fluorescence Immunohistochemistry and H-Score analysis.

ADC 3rd Generation Linker Technology with dual payload

YB-811 with 4 MMAF (non-cleavable) & 4 Exatecan (cleavable linker)

ADC developed in collaboration with T-E Meds, Taiwan:

- Linker of 3rd generation:
  - Not toxic
  - Does not lose payloads circulating in blood stream
  - Controlled release inside the tumor cell
- Experimental payloads chosen; other payloads possible





*DBCO: dibenzocyclooctyne, a reactive group that enables efficient and selective conjugation through strain-promoted azide-alkyne cycloaddition (SPAAC) reactions

ADC YB-811: 100% Tumor Eradication after Four Doses (10 mg/kg)

CDX Model: Tumor does not grow back 2 weeks after last treatment



- **Effect:**
  - **100% Tumor regression after 2 doses**
  - **100% Tumor eradication after 4 doses**
  - **No Tumor re-growth after therapy**
  - **No treatment related animal death; No weight loss**
  - **No macroscopic observations in main organs**

ADC YB-811: PDX Pancreatic Cancer in vivo test

100% Tumor Regression; better than current standard chemo therapies







- **At tolerated doses** (body weight monitoring), **results analysis indicates statistically significant marked tumor regression observed upon systemic administrations of YB-811** (10 mg/kg, i.p., QW) **in pancreatic Panc10713 PDX tumor-bearing immuno-compromised NMRI Nu/Nu female mice**

EPO's historical data with this experimental model indicate potential tumor regression with some classical potent chemotherapeutic agents

Toxicology Study

Black-6 mice treated with 10mg/kg three weeks once weekly – mice sacrificed 1 week after last dosing

Parameters	PBS Group	YB-800 Group	YB-811 Group
Weight Loss	None (weight gain)	None (weight gain)	None (weight gain)
Behavioral Change	No Observation	No Observation	No Observation
Organs macroscopic	Normal	Normal	Normal
Organs microscopic	Normal	Normal	Normal
Serum Chemistry	Normal	Normal	Normal

BEST STARTUP CATEGORY
PRIX GALIEN USA
NOMINEE 2024
Ymmunobio
3rd Place

Grant recipient of
Innosuisse
Swiss Innovation Agency

IP and Team

- ✓ World-class team with locked-in IP and strategic global collaborations
- ✓ Strong patent portfolio ensures competitive moat
- ✓ Experienced leadership and academic-industry partnerships accelerate innovation and validation

YB-800: Ymmunobio is the exclusive Patent owner

- Medical and Diagnostic Use (Method of Use - MoU)

- Composition of Matter (CoM)

NPTXR target ”locked in”; patents prevent competitors from working on NPTXR; verified by 2nd patent law firm

YB-800 patents:

1st : Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs.

2nd : A novel antibody binding specifically to NPTXR and use thereof.

Claims:	Medical use for defined cancers and Use as a diagnostic tool (1st patent) Composition of matter for optimized antibody (2nd patent)
Int. scope:	1st patent pending in EP; Granted: **US** (Oct 2023 & Sep 2024) and **JPN** Dec 2024 2nd patent pending, **EP** published in 11/2025, JPN, US, CN & SK to follow
Int. filing date:	25.01.2019 (1st patent) 15.04.2024 (2nd patent)

Experienced Executive Team

Dr. Peter Schiemann, PhD

CEO, Chairman & Co-Founder

Entrepreneur with over 30 years Experience in Pharma

Dr. Michel Janicot, PhD

Chief Development Officer

Over 35 years in Drug Development and preclinical expert in oncology

Dr. Estelle Chao, PhD, MBA

Head Business Development

Over 20 years experience in drug development

Martin E. Zuzulo, MSc

Chief Operations Officer

Over 30 years Experience in Life Sciences

Christian Germa, MSc

Chief Finance Officer

Over 25 years experience in finance

BEST STARTUP CATEGORY
PRIX GALIEN USA
NOMINEE 2024

Ymmunobio
3rd Place

Grant recipient of
Innosuisse
Swiss Innovation Agency

Ymmunobio

Thank you!

PETER SCHIEMANN, PHD
CEO & Chairman

peter.schiemann@ymmuno.bio

+41-76-378 59 30
+1-908-294-1212

Disclaimer

All the information contained in this document is provided for information purposes only and does not constitute, and should not be viewed as, an offer, invitation or solicitation to take any action, or as the sole basis for any investment decision or a recommendation to buy the company's securities.

The contents of this document were carefully prepared and researched. Notwithstanding this, the company makes no guarantee that the information presented here is correct, complete or current.

Furthermore, the company accepts no liability for any direct or indirect losses, liability claims, costs, demands, expenses or damages, whatever their nature, arising from or connected with the use of all or part of the information contained in this document.

All statements other than statements of scientific facts contained in this document are forward-looking statements or opinions. Such forward-looking statements and opinions involve known and unknown risks, uncertainties, and other factors, which can result in the actual results, financial situation, evolution or performance of the company differing substantially from that directly or indirectly referred to in those forward-looking statements or opinions. Given these uncertainties, potential investors should not rely on these forward-looking statements and opinions.

The company cannot guarantee that the opinions and forward-looking statements contained in this document prove to be correct.

The company assumes no responsibility or duty to update these forward-looking statements publicly or to adapt them to reflect future events, developments or expectations.